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INTRODUCTION 
 Approximately half of patients with Graves’ disease have ocular involvement (Graves’ orbitopathy, 
GO).
1
  Moderately severe and active forms of GO can be effectively treated with glucocorticoids and/or 
orbital irradiation.
1,2
 Milder forms of GO may improve spontaneously and generally require only local 
measures (artificial tears, ointments, prisms) to control mild symptoms.  
A “wait-and-see strategy” in which patients are followed until symptoms may worsen can be 
challenged. First, many patients with even mild GO suffer from a substantial decrease in their quality of life 
(QoL) as assessed by either general health-related QoL
3
 or disease specific (GO-QoL) questionnaires.
4
 
Second, in a natural history study of mild GO, spontaneous improvement occurred in about 20% of patients, 
but eye disease remained static in 65%, and disease progressed in 15%.
5
 Thus, therapy would seem justified. 
Treatment should be cheap, well tolerated and widely available. Two potential agents that may inhibit 
pathogenic mechanisms believed to be relevant in GO are selenium and pentoxifylline.  
Selenium is a trace mineral and an essential nutrient for selenocysteine synthesis.
6
 Selenocysteine is 
incorporated into several selenoproteins, mostly enzymes, in which selenium acts as a redox center and 
functions as an antioxidant. A number of in vitro studies suggest that increased generation of free oxygen 
radicals plays a pathogenic role in GO. 
7-9
 Selenium also has an important influence on the immune system
6, 
10
 and might be beneficial in Hashimoto’s thyroiditis11-12 and Graves’ disease. 13  
Pentoxifylline is a nonspecific phosphodiesterase inhibitor used for the treatment of intermittent 
claudication.
14
 It also has anti-inflammatory and immunomodulatory effects 
15-17
and an in vitro inhibitory 
effect on HLA-DR expression and glycosaminoglycan secretion by orbital fibroblasts.
18-19
 All of these 
factors are relevant to the pathogenesis of GO.
20-21
 One small pilot study suggested that pentoxifylline might 
be beneficial for GO.
22
  
The European Group on Graves’ Orbitopathy (EUGOGO; http://www.eugogo.eu) now reports a 
multicenter, randomized, double-blind, placebo-controlled clinical trial that investigated whether selenium 
or pentoxifylline may be beneficial for mild GO. 
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PATIENTS AND METHODS 
Patients and Study Design 
During the study period all consecutive patients who had mild signs and/or symptoms of GO under 18 
months duration, seen at 6 EUGOGO centers [Amsterdam (NL), Mainz (D), Olten (CH), Pisa (I), 
Thessaloniki (GR) and Varese (I)], were invited to participate in the study if they qualified, according to 
inclusion and exclusion criteria (Supplemental Table 1).  
The study asked whether selenium or pentoxifylline in comparison with placebo could affect the 
course of GO, (either by enhancing improvement or preventing worsening), and improve the GO-QoL.
1
 The 
study lasted one year and consisted of a 6-month period of intervention followed by a 6-month period of 
follow-up. Drugs or placebo were administered orally.  
Selenium was given as selenium selenite (100 g bid). Pentoxifylline (Trental®Aventis) was given at a 
dose of 600 mg bid. Placebo was administered twice a day. Selenium and placebo capsules were prepared to 
look identical to pentoxifylline by Gelphipharma (Italy).  
Patient randomization was done centrally in the Amsterdam office with stratification per center in 
blocks of 6 sealed envelopes into which in random order a had been inserted  that noted Lot 1 (twice), Lot 2 
(twice), or Lot 3 (twice). Drugs were delivered in identical boxes (Lot 1, Lot 2, and Lot 3), and tablets were 
given to the patients by the local endocrinologist, who was blinded to the content of Lots 1, 2 and 3. 
Ethical approval was obtained from the institutional boards of participating centers. Written informed 
consent was obtained from all participants prior to enrollment. The trial was approved by Medical Ethical 
Committee of the Academic Medical Center at the University of Amsterdam (MEC 03/119) on July 2004, registered 
by Nederland’s Trial Register (NRT524) on December 2005 and by the EudraCT (number 2006-003021-81). 
The study was designed by the EUGOGO group; all authors gathered and vouched for the data. 
Statistical analysis was performed by WB. CM wrote the first draft of the paper, and all authors revised and 
decided to publish it. 
Study Procedures and Endpoints 
Patients were studied at baseline and after 3, 6 and 12 months. Eye evaluation was performed by a 
blinded ophthalmologist using a modified EUGOGO Case Record Form (http://www.eugogo.eu). At each 
 4 
center the same ophthalmologist evaluated the patients during follow up and recorded eyelid aperture in mm, 
soft tissue involvement according to the Color Atlas,
23
exophthalmos in mm using the same Hertel 
exophthalmometer in each center, eye muscle involvement by measuring extension of ductions in degrees, 
and visual acuity using the Snellen chart in decimals. 
The Clinical Activity Score consists of 7 items, and the final score is the sum of all items present
24
 -- 
spontaneous retrobulbar pain, pain on attempted up-, side- or down-gaze, conjunctival redness, redness of 
the eyelids, chemosis, swelling of the caruncle, and swelling of the eyelids.  
Gorman’s diplopia score25 includes four categories- no diplopia (absent), diplopia when tired or when 
first awakening (intermittent), diplopia at extremes of gaze (inconstant), and continuous diplopia in the 
primary or reading position (constant). 
QoL was evaluated using the GO-QoL previously validated,
4, 26
 and available in several languages 
(http://www.eugogo.eu). 
Blood was taken at all visits for assessment of thyroid function (serum free T4, total or free T3, TSH) 
and autoantibodies against thyroid peroxidase (TPOAb) and the TSH-receptor (TRAb)]. Side effects were 
recorded at all follow-up visits.  
There were two primary outcome measurements- first the assessment of the eye changes by a blinded 
ophthalmologist, and second the GO-QoL questionnaire filled in by the masked patient.  
The primary endpoints were comparisons of rates of GO outcomes [overall ophthalmic assessment and 
GO-QoL, scored as improvement, no change, worsening (Supplemental Table 1)] at 6 months between 
patients assigned to either active treatments or placebo. The overall ophthalmic outcome is a composite 
score based on multiple items; the use of a composite score circumvents the problem arising from the 
presence of improvement in one item and simultaneous worsening in another one.  
Secondary outcome measurements were the changes of the diplopia score and the 7-item CAS at 6 
months.  
The 12-month observation was scheduled as exploratory for the sole purpose of evaluating whether or 
not the effects at 6 months were maintained.  
The visit at three months was scheduled to check thyroid status and adherence to treatment.  
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Statistical Analysis 
The study was aimed at separately comparing selenium vs. placebo and pentoxifylline vs. placebo. The 
sample size was calculated based on the results of a previous observational study in patients with GO that 
showed improvement in 20%, no change in 65% and worsening in 15% of patients without specific 
treatment.
5
 The present study tested the hypothesis that treatment with selenium or pentoxifylline would 
result in an increase of 25% (from 20% to 45%) in the proportion of patients showing improvement at 6 
months of treatment. To detect such a difference with 80% power and a significance of 0.05, each study arm 
was planned to comprise 52 patients. 
Patients withdrawn from the study because of side effects, lack of adherence, or progression of GO 
requiring specific treatments for the eye disease were kept in the primary analysis (premature stops), 
provided they were available for evaluation at the third month visit. The results of their last assessment were 
carried forward and evaluated as the last visit. Patients lost to follow-up before the second visit at 3 months 
were excluded from the analysis.  
Categorical variables were compared by χ2 or the Fisher exact test. The two-sided t test and the Mann-
Whitney test were used to evaluate differences in the changes of GO-QoL and CAS at 6 and 12 months vs. 
baseline between active treatment groups and placebo group, respectively. The thyroid autoantibody levels 
at the end of treatment (6 months) vs baseline were compared by the Paired Sign test for TPOAb (in view of 
the use of different assay methods in different centers) and the Wilcoxon Signed Rank test for TRAb. 
Prevention of deterioration of GO was evaluated by comparing the number of patients who 
experienced worsening of eye signs to those in whom the eye disease either improved or remained 
unchanged. 
A P value <0.05 was considered as significant. The Benjamini-Hochberg correction for multiple 
comparisons was to be used for differences in the primary endpoint outcomes.
27
 P values computed for 
secondary endpoints and for endpoints at 12 months are exploratory. 
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RESULTS 
Patients 
From January 2005 to January 2009 204 eligible patients were invited to participate in the study (Fig. 
1). Forty-five declined, and 159 were randomized (placebo n=52, selenium n=55, pentoxifylline n=52). The 
clinical characteristics of the patients who declined did not differ from those randomized. Seven patients left 
the study during the first month [due to consent withdrawal (2 in the placebo group and 1 in the selenium 
group) or drug-related side effects (4 in the pentoxifylline group)] and were not included in the final 
analysis. The remaining 152 patients (placebo n=50, selenium n=54, pentoxifylline n=48) underwent at least 
the first 3-month evaluation and were kept in the final analysis.  
The baseline characteristics of the study patients and the number recruited per center are reported in 
Table 1.  
One-hundred-thirty-seven patients (90.1%) completed the study [43 placebo (86.0%), 52 selenium 
(96.3%) and 42 pentoxifylline (87%)]. Premature stops (n=15) were due to lack of adherence (5, 2 and 2, 
respectively, in the three groups), side effects (0, 0, 3, respectively) or progression of GO requiring 
treatment with intravenous glucocorticoids and/or orbital radiotherapy (2, 0, 1, respectively).  
Thyroid function tests confirmed euthyroidism in all patients; a few required minor adjustment of 
antithyroid drug (ATD) or levothyroxine (LT4) dosage. TPOAb declined in the selenium (P=0.001) and 
pentoxifylline group (P=0.02), but not in the placebo group (P=0.4), whereas TRAb declined in all three 
groups (P=0.002, P=0.002 and P=0.004, respectively; Supplemental Table 2). 
 
Primary and Secondary Endpoints 
The mean GO-QoL scores before and after intervention are shown in Table 2. The baseline scores 
showed a mild to moderate impairment in GO-QoL, with no significant differences among the three groups 
in visual functioning and appearance scores. Compared with baseline at 6 months 33 out of 53 (62.3%) 
patients given selenium showed an increased 6 points in visual functioning and 40 out of 53 (75.5%) in 
appearance. As shown in Fig. 2, Panel A, a significantly greater proportion of patients in the selenium group 
showed an improvement in the GO-QoL at 6 month compared with placebo. Moreover, selenium 
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substantially decreased the rate of worsening of GO-QoL compared with placebo [9/53 (17.0%) vs. 20/46 
(43.5%), respectively; (P=0.004)].  
The overall ophthalmic outcome at the 6-month evaluation differed between the selenium and the 
placebo groups (P=0.01), whereas there was no difference between the pentoxifylline and placebo groups 
(P=0.12, Fig. 2, Panel B). GO improved in 18/50 patients (36.0%) in the placebo group, 33/54 patients 
(61.1%) in the selenium group and 17/48 (35.4%) in the pentoxifylline group, and worsened in 13/50 
patients (26.0%) in the placebo group, 4/54 (7.0%) in the selenium group and in 5/48 (10.4%) in the 
pentoxifylline group. The rate of worsening of GO in the selenium group was lower than in the placebo 
group (P=0.01).  
Because each of the primary outcome measurements at 6 months were statistically significant the use 
of the Benjamini-Hockberg correction was not necessary. 
Changes in individual parameters on which the overall ophthalmic outcome was based are reported in 
Table 2. Improvement in lid aperture and soft tissue involvement, rather than changes in proptosis and eye 
motility, were the major determinants of the overall ophthalmic outcome in patients treated with selenium. 
The median and range of the eyelid aperture reduction was 2 mm (2, 3 mm) at 6 months and 3 mm (2,4 mm) 
at 12 months. A large proportion of selenium-treated patients who improved in eyelid aperture and/or soft 
tissue changes also had an improvement of 6 or more points in the appearance and functioning scales of GO-
QoL, as well as in the overall GO-QoL evaluation, at 6 months [27/32 (84%, C.I. 67-95), 23/32 (71.9%; CI 
53-86) and 26/32 (81.2%, C.I. 63-93), respectively]. 
The beneficial effect of selenium on GO-QoL and overall eye evaluation persisted 6 months after 
withdrawal of therapy and the outcome of selenium-treated patients continued to be better compared with 
placebo (P<0.001 and P=0.007, respectively; Supplemental Table 3). 
Visual acuity was normal in all patients at baseline and did not change during the 12-month follow up. 
There was no apparent influence of smoking status on the effect of different treatments in either the 
primary outcomes in the overall study population or in any arm of the study. 
Extraocular muscle dysfunction did not significantly change during the study in any group (data not 
shown). 
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The mean CAS decreased in all groups (Table 2). The CAS reductions at 6 and 12 months were 
significantly greater in the selenium group than in the placebo group. No difference was observed between 
the pentoxifylline and placebo groups.  
Adverse Events 
Drug-related side effects (skin and gastrointestinal) occurred in 7 patients treated by pentoxifylline (4 
left the study during the first month) and in none receiving either selenium or placebo (Table 3).  
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DISCUSSION 
In our trial selenium, as compared with placebo, resulted in significant improvement in the QoL, as 
assessed by a disease-specific (GO-QoL) questionnaire.
4
 The improvement affected both appearance and 
visual functioning scores and is likely due to amelioration in soft tissue changes and eyelid aperture, which 
occurred in most of the patients showing an improvement in GO-QoL scores. Neither pentoxifylline nor 
placebo caused significant changes in the QoL.  
The beneficial effect of selenium on QoL was corroborated by a significantly better outcome of eye 
signs, as compared with placebo, at the end of the 6-month treatment period. GO improved in 33 of 54 
patients, mainly due to an amelioration of soft tissue changes and a decrease in eyelid aperture. Four patients 
given selenium showed a mild progression of GO that required only local measures. In the placebo group 
GO improved in 18 of 50 patients and progressed in 13, two of whom required major intervention for GO. 
Thus, compared to placebo, selenium was associated with an increased rate of improvement of GO but also 
a decreased rate of worsening. Except for a transient benefit on soft tissue changes at 6 months, the outcome 
of pentoxifylline did not differ from that of placebo.  
The CAS in the selenium group was significantly lower than in the placebo group at 6 months. 
However, the CAS decreased in all three groups, probably reflecting the spontaneous trend of mild GO to 
become less active or inactive in most cases.  
Exploratory evaluation at 12 months confirmed the results at 6 months. 
Graves’ disease is characterized by an increased oxidative stress,28,29 and increased generation of free 
oxygen radicals might play a role in the pathogenesis of GO.
7-9
 Serum selenoprotein P levels, an index of the 
oxidative state, are lower in   GO patients than in controls, with a weak inverse correlation with GO 
activity.
30
 In contrast, a recent report showed no difference in selenium levels in patients with mild GO and 
controls.
31
 Thus, we speculate that an intervention aimed at improving the imbalance of the 
antioxidant/oxidant status might be helpful both for hyperthyroidism and GO. Anti-thyroid drug therapy in 
patients with Graves’ disease decreases generation of reactive oxygen species28and euthyroidism was more 
rapidly reached when antioxidant supplementation (including selenium) was added to methimazole
13
. 
Graves’ patients with remission of hyperthyroidism after anti-thyroid drug therapy showed higher selenium 
concentrations than patients who relapsed, and TSH receptor antibody levels were negatively correlated with 
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serum selenium concentrations
32
. In a previous non-randomized study in patients with moderate-severe GO 
antioxidant therapy with allopurinol and nicotinamide compared with placebo was shown to be beneficial 
for GO.
33
 
Our study has two potential limitations. First, we do not have data on the changes in serum selenium 
concentrations following selenium selenite administration. Second, although we did not measure selenium 
levels in patient sera before and during selenium selenite administration, most patients came from areas in 
which selenium levels are known to be marginally decreased in the general population. 
6,34,35
 As reported in 
other studies, the marginal selenium deficiency may have favored the beneficial effect of selenium 
supplementation.
6
 Similar studies performed in selenium sufficient areas would be helpful in addressing this 
issue.  
In summary, our data indicate that supplementation with selenium for six month improves the course 
of GO and GO-related impairment of the quality of life. 
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Table 1. Baseline Characteristics of the Patients 
1,2
 
Variable Selenium 
(N=54) 
Placebo 
(N=50) 
Pentoxifylline 
(N=48) 
Demographic characteristics    
Age-yr 43.0 (11.0) 44.6 (10.7) 43.7 (12.4) 
Female sex 48 (88.9%) 41 (82.0%) 37 (77.1% 
Race    
  White 52 (96.4%) 50 (100%) 48 (100%) 
  Asian 1 (1.8%) 0 0 
  Black 1 (1.8%) 0 0 
Thyroid disease    
  Graves’ disease 51 (94.4%) 43 (86.0%) 46 (95.8%) 
  Chronic autoimmune thyroiditis 2 (3.7%) 3 (6.0%) 2 (4.1%) 
  Euthyroid Graves’ disease 1 (1.9%) 4 (8.0%) 0 
Previous thyroid treatment    
  Radioiodine 4 (7.4%) 4 (8.0%) 6 (12.5%) 
  Thyroidectomy 4 (7.4%) 9 (18.0%) 6 (12.5%) 
Current thyroid treatment    
  Antithyroid drugs 
3
 41 (75.9%) 34 (68.0%) 35 (72.9%) 
  Levothyroxine 9 (16.7%) 9 (18.0%) 11 (22.9%) 
  None 4 (7.4%) 7 (14.0%) 2 (4.2%) 
Duration of eye symptoms/signs – months 7.7 (5.8) 6.1 (4.6) 6.0 (4.6) 
Current smokers 23 (42.6%) 25 (50.0%) 17 (35.4%) 
Biochemical characteristics    
TSH – mU/liter 0.6 (0.3, 2.1) 0.7 (0.3, 2.0) 1.1 (0.5, 2.2) 
TRAb (IU/liter) 6.8 (3.5, 23.0) 4.3 (2.0, 15.0) 4.4 (1.3, 11.0) 
TRAb positive 
4
 32 (68.1%) 30 (73.2%) 27 (65.8%) 
TPOAb positive 
4
 32 (68.1%) 27 (65.9%) 26 (63.4%) 
Eye symptoms and signs 
5
    
Proptosis – mm 19.7±2.7 19.8±2.3 20.0±2.5 
Eyelid width  – mm 11.5±1.9 11.3±1.7 11.6±2.1 
Soft tissue involvements    
  Absent 5 (4.6%) 5 (5.0%) - 0 
  Mild 64 (59.3%) 65 (65.0%) 52 (54.2%) 
  Moderate 39 (36.1%) 30 (30.0%) 44 (45.8%) 
Diplopia (Gorman’score) 6    
  No diplopia 43 (79.6%) 44 (88.0%) 43 (89.6%) 
  Intermittent 6 (11.1%) 3 (6.0%) 2 (4.2%) 
  Inconstant 5 (9.3%) 3 (6.0%) 3 (6.2%) 
Clinical Activity Score (0-7)
 7
 3.5 (3.0, 4.0) 3.0 (2.0, 4.0) 3.0 (2.0, 5.0) 
 
1
 Patients were recruited at the following EUGOGO Centers: Mainz, Germany (n=48); Thessaloniki, Greece (n=33); Pisa, Italy 
(n=24), Varese, Italy (n=20), Amsterdam, The Netherlands (n=19) and Olten, Switzerland (n=8). 
2 Unless otherwise stated data are means (SD) or numbers (%), or median (25th, 75 th centiles).  
3 Antithyroid drugs used were methimazole, carbimazole and propylthiouracil. 
4
 TRAb (TSH receptor autoantibodies) and TPOAb (thyroid peroxidase autoantibodies) status was determined in 41 patients in 
the placebo group, 47 patients in the selenium group, and 41 in the pentoxifylline group. 
5
 Proptosis and eyelid width are the average of measurements in both eyes; soft tissue involvement is referred to each eye. 
6
 Intermittent, present only when tired or on waking; Inconstant, present in secondary positions of gaze; Constant, present in 
primary and reading positions. 
7
 The Clinical Activity Score is the sum of single scores, ranging from 0 (no activity) to 7 (maximal activity) 
24
. One point 
is given to each of the following items, if present: spontaneous retrobulbar pain, pain on eye movements, eyelid erythema, 
conjunctival injection, chemosis, swelling of the caruncle, eyelid edema or fullness.
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Table 2. Graves’ Orbitopathy Specific Quality of Life (GO-QoL), Clinical Activity Score (CAS) and Eye Evaluatiuon 
Before and After Different Treatments 
 
GO-QoL1, 2 Selenium 
(n=53) 
P value Placebo 
(n=46) 
P value Pentoxifylline 
(n=41) 
Visual functioning      
  Baseline 80.1±17.1 0.29 4 84.0±19.5 0.11 5 77.8±16.6 
  Δ 6 months 8.73±17.7 0.001 4 -2.4±14.6 0.52 5 -0.21±18.0 
  Δ 12 months 11.0±15.3 0.004 4 -1.7±18.7 0.80 5 -0.64±18.1 
      
Appearance      
  Baseline 74.0±19.8 0.15 4 79.5±18.1 0.24 5 75.0±18.3 
  Δ 6 months 10.6±10.9 <0 001 4 -2.6±11.7 0.73 5 -1.7±13.8 
  Δ 12 months 12.6±11.8 <0.001 4 -1.6±17.1 0.85 5 -0.9±16.3 
      
CAS 3 Selenium 
(n=54) 
P value Placebo 
(n=50) 
P value Pentoxifylline 
(n=48) 
  Baseline 3.5 (3.0, 4.0) 0.17 6 3.0 (2.0, 4.0) 0.60 7 3.0 (2.0, 5.0) 
  Δ 6 months -1.9±1.3 <0.001 6 -0.6±1.9 0.24 7 -0.9±1.4 
  Δ 12 months -2.2±1.3 <0.001 6 -1.0±2.3 0.30 7 -1.4±1.6 
      
EYE EXAMINATION 8  Selenium 
(n=54) 
 P value  Placebo 
(n=50) 
 P value  Pentoxifylline 
(n=48) 
Eyelid aperture      
  6 months n (%)      
    Improved 20/54 (37.0)  
0.01 9 
6/50 (12.0)  
0.7 99 
7/48 (14.7) 
    No change 28/54 (51.9) 38/50 (76.0) 37/48 (77.0) 
    Worsening 6/54 (11.1) 6/50 (12.0) 4/48 (8.3) 
  p value 10 0.92  0.36  0.64 
  12 months n (%)      
    Improved 21/54 (38.9)  
0 03 9 
10/50 (20.0)  
0.54 9 
9/48 (18.8) 
    No change 26/54 (48.1) 37/50 (74.0) 33/48 (68.7) 
    Worsening 7/54 (13.0) 3/50 (6.0) 6/48 (12.5) 
      
Soft tissue signs      
  6 months n (%)      
    Improved 23/54 (42.6)  
0.04 9 
16/50 (32.0)  
0.02 9 
20/48 (41.7) 
    No change 28/54 (51.8) 23/50 (46.0) 26/48 (54.2) 
    Worsening 3/54 (5.6) 11/50 (22.0) 2/48 (4.1) 
  p value 10 0.30  0.97  0.69 
  12 months n (%)      
    Improved 31/54 (57.4)  
0.005 9 
16/50 (32.0)  
0.22 9 
20/48 (41.7) 
    No change 21/54 38.9) 24/50 (48.0) 24/48 (50.0) 
    Worsening 2/54 (3.7) 10/50(20.0) 4/48 (8.3) 
      
Proptosis      
  6 months n (%)      
    Improved 6/54 (11.1)  
0.48 9 
3/50 (6.0)  
0.60 9 
5/48 (10.4) 
    No change 45/54 (83.3) 42/50 (84.0 40/48 (83.3) 
    Worsening 3/54 (5.6) 5/50 (10.0) 3/48 (6.3) 
  p value 10 0.36  0.37  0.43 
  12 months n (%)      
    Improved 9/54 (16.7)  
0.93 9 
7/50 (14.0)  
0.99 9 
7/48 (14.6) 
    No change 39/54 (72.2) 37/50 (74.0) 35/48 (72.9) 
    Worsening 6/54 (11.1) 6/50 (12.0) 6/48 (12.5) 
      
Eye muscle motility      
  6 months n (%)      
    Improved 2/54 (3.7)  
0.35 9 
5/50 (10.0)  
0.60 9 
3/48 (6.3) 
    No change 50/54 (92.6) 42/50 (84.0) 40/48 (83.3) 
    Worsening 2/54 (3.7) 3/50 (6.0) 5/48 (10.4) 
  p value 10 0.90  0.76  0.59 
  12 months n (%)      
    Improved 3/54 (5.6)  
0.27 9 
5/50 (10.0)  
0.23 9 
1/48 (2.1) 
    No change 49/54 (90.7) 40/50 (80.0) 42/48 (87.5) 
    Worsening 2/54 (3.7) 5/50(10.0) 5/48 (10.4) 
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1
 Graves’ orbitopathy specific quality of life (GO-QoL) questionnaire measures health-related quality of life of patients with 
Graves’ orbitopathy 4 (see footnotes of Table 1) Healthy subjects should score 100 points (no limitations). Data are presented 
as mean±SD. 
2
 GO-QoL questionnaires were incompletely filled or missing in 12 patients (1 in the selenium group, 4 in the placebo group and 
7 in the pentoxifylline group) 
3
 The Clinical Activity Score is the sum of single scores, ranging from 0 (no activity) to 7 (maximal activity) 
24
. One point is 
given to each of the following items, if present: spontaneous retrobulbar pain, pain on eye movements, eyelid erythema, 
conjunctival injection, chemosis, swelling of the caruncle, eyelid edema or fullness. Data are median (25
th
, 75
th
 centiles) 
4
 Selenium vs placebo by two-sided t test 
5
 Pentoxifylline vs placebo by two-sided t test 
6
 Selenium vs placebo by Mann-Whitney test 
7
 Pentoxifylline vs placebo by Mann-Whitney test 
8
 Changes were graded as improved, no change and worsened, according to predefined criteria, as reported in Supplemental 
Table 1 
9 P value vs placebo by 3x2 χ2-test 
10 P value 6 months vs 12 months  by 3x2 χ2-test 
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Table 3. Adverse Events 
 
Event Selenium 
(N=55) 
Placebo 
(N=52) 
Pentoxifylline* 
(N=52) 
Bloating 0 0 1 
Abdominal discomfort 0 0 1 
Nausea 0 0 3 
Erythema 0 0 1 
Pruritus 0 0 1 
* Four patients left the study during the first month and were not included in the final analysis. 
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FIGURE LEGENDS   
Fig. 1. Enrollment, Randomization and Follow-up of Study Patients 
Seven of the 159 randomized patients were not included in the intention-to-treat analysis because  they 
withdrew consent (n=3) or discontinued therapy before the first 3-month evaluation for drug-related side 
effects (n=4).  
Fig. 2. Primary Endpoints.  
Panel A shows the changes in GO-QoL at 6- (upper panel) and 12- (lower panel) evaluation. GO-QoL is a 
disease-specific quality of life questionnaire filled in by the masked patient which measures limitations in 
visual functioning (as a consequence of diplopia and/or decreased visual acuity) and limitations in 
psychosocial functioning (as a consequence of a changed appearance). Panel B shows the changes in the 
overall eye evaluation at 6- (upper panel) and 12-month- (lower panel) performed by a blinded 
ophthalmologist. Changes in GO-QoL and overall eye evaluation were graded as improved, no change and 
worsened, according to predefined criteria, as reported in Supplemental Table 1. 
Differences in proportions were tested using the contingency 3x2 χ2-test.   
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Supplemental Table 1. Criteria for Patient Eligibility at Baseline and Primary Outcomes Evaluation. 
_________________________________________________________________________ 
Criteria for Patient Eligibility  
Inclusion criteria 
a) Presence of at least one sign of mild GO [soft tissue swelling NO SPECS class 2a and 2b 20 (e.g., 
chemosis; mild to moderate eye lid swelling) according to Color Atlas 
23
 ; exophthalmos 22 mm; see 
also exclusion criteria], with a disease duration of less than 18 months (as recorded by the patient); 
b) No previous specific therapy for GO, except for local measures; 
c) Euthyroidism as a result of remission after a course of antithyroid drug (ATD) therapy, or euthyroidism 
for at least 2 months since commencing ATD or after thyroidectomy, or euthyroidism for at least 6 
months after radioiodine (RAI) therapy. Hypothyroid patients after thyroidectomy or radioiodine were 
replaced with levothyroxine (LT4). Euthyroidism was defined as normal serum free T4, free (or total) 
triiodothyronine (T3) concentrations, and thyrotropin (TSH) levels below 4 mU/Liter. Patients were 
kept euthyroid for the whole duration of the study;  
d) Age 18-70 years. 
Exclusion criteria 
a. Soft tissue swelling NO SPECS class 2c (e.g. severe chemosis, severe eye lid swelling) according to the 
Color Atlas 
23
 ; 
b. Exophthalmos >22 mm; 
c. Diplopia in primary or reading position, and/or ocular torticollis; 
d. Mono-ocular duction in any direction of less than 20 degrees; 
e. Signs or symptoms of dysthyroid optic neuropathy; 
f. Other exclusion criteria were: pregnancy, drug and/or alcohol abuse, severe concomitant illness, 
inability to comply with the study protocol, no informed consent, or current use of selenium- or 
pentoxifylline-containing preparations. 
_________________________________________________________________________ 
Primary outcomes evaluation 
Overall ophthalmic outcome was defined as follows: 
1. Improvement, when at least one of the following outcome measures improved in one eye, without 
worsening in any of these measures in either eyes: 
a. Reduction of eyelid aperture by at least 2 mm; 
b. Reduction in any of the Class 2 signs by at least one grade in the NOSPECS classification 21; 
c. Reduction in exophthalmos by at least 2 mm; 
d. Reduction in ocular motility by at least 8 degrees in any duction. 
2. Deterioration, if any of the following occurred: 
a. Worsening by at least one grade in any of the NOSPECS classes 21; 
b. Appearance of a new NOSPECS class 21; 
c. Decrease in visual acuity due to optic nerve involvement by at least one line on the Snellen chart, 
or other evidence (i.e., impaired color vision) or suspicion of optic nerve compression. 
GO specific Quality of Life (GO-QoL) questionnaire 
*
 
1. Improvement, if there was an increase of 6 or more points on either one (or both) the GO-QoL scales 
(functioning and appearance)
 **
.  
2. Deterioration, if there was a decrease of 6 points on any one of the two scales. 
* 
Graves’ orbitopathy specific quality of life (GO-QoL) questionnaire measures health-related quality of life of patients with 
Graves’ orbitopathy 4. It measures limitations in visual functioning as a consequence of diplopia and/or decreased visual acuity 
(8 questions), and limitations in psychosocial functioning as a consequence of a changed appearance (8 questions).
 
** 
A change of at least 6 points on one or both GO-QoL subscales was considered as an important change in daily functioning for 
GO patients
26
. This cut-off value was derived from a previous study in which the minimal clinically important difference 
(MCID), defined as the smallest difference in score on the domain of interest which patients perceive as benefit and which 
would mandate, in the absence of troublesome side effects and costs, a change in the patient’s management in either GO-QoL 
subscales appeared to be 6 points. 
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Supplemental Table 2. Mean (SD) thyroid autoantibody levels before and after different treatments  
________________________________________________________________________________ 
Group Baseline 
1
 6 months P  
Placebo 
 TPOAb (U/mL) 1024±1108 733±882 0.4 
2
  
 TRAb (IU/L) 21.0±25.8 10.6±10.4 0.004 
3
  
 
Selenium 
 TPOAb (U/mL) 735±732 605±913 0.001 
2
  
 TRAb (IU/L) 21.1±30.7 12.4±29.1 0.002 
3
  
 
Pentoxifillyne 
 TPOAb (U/mL) 807±892 563±541 0.02 
2
  
 TRAb (IU/L) 13.7±16.7 6.1±5.4 0.002 
3
  
 
1 
P>0.05 for all comparisons between treatment groups Kruskall-Wallis. 
2 
vs baseline values by the Paired Sign test. 
3 
vs. baseline values by the Wilcoxon signed rank test.  
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Supplemental Table 3:. Primary outcomes 
____________________________________________________________________________________________________________________ 
  Selenium P value
1
 Placebo P value
1
 Pentoxifylline 
____________________________________________________________________________________________________________________ 
GO-QoL  
 6 months n (%) 
  Improved 39/53 (73.6)   11/46 (24.0)  14/42 (33.3) 
  No change 5/53 (9.4) <0.001 15/46 (32.6) 0.57 12/42 (28.5) 
  Worsening 9/53 (17.0)  20/46 (43.5)  15/42 (35.7) 
 P value
2
 0.84  0.05  0.70 
 12 months n (%) 
  Improved 40/53 (75.5)  19/46 (41.3)  14/42 (33.3) 
  No change 6/53 (11.3) <0 001 6/46 (13.0) 0.52 9/42 (21.4) 
  Worsening  7/53 (13.2)  21/46 (45.7)  18/42 (42.8) 
 
Overall eye evaluation  
 6 months n (%) 
  Improved 33/54 (61.1)  18/50 (36.0)  17/48 (35.4) 
  No change 17/54 (31.5) 0.01 19/50 (38.0) 0.12 26/48 (53.2) 
  Worsening 4/54 (7.4)  13/50 (26.0)  5/48 (10.4) 
 P value
2
 0.68  0.92  0.60 
 12 months n (%) 
  Improved 36/54 (66.7)  19/50 (38.0)  18/48 (37.5) 
  No change 13/54 (24.1) 0.007 17/50 (34.0) 0.37 22/48 (45.8) 
  Worsening 5/54 (9.2)  14/50(28.0)  8/48 (16.7) 
___________________________________________________________________________________________________________________ 
1
 P value vs placebo by 3x2 χ2-test 
2 P value 6 months vs 12 months  by 3x2 χ2-test 
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Fig 1 
 
Eligible 
(n=204) 
Declined to participate (n= 45) 
Randomized (N= 159) 
Allocated to placebo (n= 52) 
• Received allocated intervention (n= 50) 
• Did not received allocated intervention  
  (consent withdrawal) (n= 2) 
Allocated to selenium (n= 55) 
• Received allocated intervention (n= 54) 
• Did not received allocated intervention  
  (consent withdrawal) (n= 1) 
Allocated to pentoxifylline (n= 52) 
• Received allocated intervention (n= 52) 
50 were included in the analysis 54 were included in the analysis 48 were included in the analysis 
Discontinued therapy before 
first evaluation (side effects) 
(n= 4) 
Discontinued intervention (n= 7) 
• Lack of compliance (n=5) 
•  Progression of 
ophthalmopathy (n= 2) 
Discontinued intervention (n= 2) 
• Lack of compliance (n=2) 
Discontinued intervention (n= 6) 
• Lack of compliance (n=2) 
• Side effects (n= 3) 
• Progression of ophthalmopathy (n= 1) 
43 completed the 
study 
52 completed the 
study 
42 completed the 
study 
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